Nanotheranostics for Cancer Applications

About the Editors.- List of Contributors.- Part I Introduction to Cancer and Nanotechnology.- 1 Introduction.- 2 Biological Events and Barriers to Effective Delivery of Cancer Therapeutics.- 3 Cancer Diagnostics and Therapeutics.-  4 Nanomedicine in Cancer.- 5 Theranostics: A Historical Perspective of Cancer Nanotechnology Paving the Way for Simultaneous Use Applications.- Part II Cancer Nanodiagnostics and Nanotherapeutics.- 6 In Vitro Cancer Diagnostics.- 7 Translational Nanodiagnostics for In Vivo Cancer Detection.- 8 Delivery of Cancer Nanotherapeutics.- 9 Oral Nanotherapeutics for Cancer with Innovations in Lipid and Polymeric Nanoformulations.- 10 Topical and Transdermal Nanomedicines for Cancer Therapy.- 11 Cancer Nanotherapeutics Administered by Non-Conventional Routes.- Part III Regulatory Considerations for Nanomaterial Drug Products.- 12 Regulatory Considerations for Cancer Drug Products Containing Nanomaterials.- 13 Perspectives for Characterizing Drug Component of Theranostic Products Containing Nanomaterials.- Part IV Cancer Nanotheranostics.- 14 Engineering Multifunctional Nanomedicine Platforms for Drug Delivery and Imaging.- 15 Image-Guided Drug Delivery.- 16 Nanotheranostics-Based Imaging for Cancer Treatment Monitoring.- 17 Remotely-Triggered Nanotheranostics.- 18 Concluding Remarks and the Future of Nanotheranostics.- Index.

Prakash Rai, PhD joined the department of Chemical Engineering at the University of Massachusetts, Lowell as an Assistant Professor in September 2012. Prior to this he was an Instructor at the Center for Engineering in Medicine at Massachusetts General Hospital (MGH) and Harvard Medical School. He received his Bachelor's degree in Chemical Engineering from the University of Mumbai, India in 2003 and his Ph.D. in Chemical and Biological Engineering from Rensselaer Polytechnic Institute in 2007. He is currently working on developing translational nanotechnology-based platforms for the imaging, prevention, and treatment of cancer. His research involves designing, synthesizing, characterizing, and evaluating the efficacy of these multifunctional nanoparticles in cell culture as well as animal models of the disease. He has authored over 30 publications in peer reviewed journals with several first author publications in journals including Nature Biotechnology, Proceedings of the National Academy of Sciences, Angewandte Chemie, and Cancer Research. In 2010, he was chosen to receive the "Scholar in Training" award by the American Association of Cancer Research. He has also received a cancer nanotechnology "Pathway to Independence" grant award from the National Cancer Institute at the National Institutes of Health to carry out research in the area of cancer theranostics.

Stephanie Morris, PhD joined the National Institutes of Health (NIH) as a Program Director at the National Cancer Institute in 2012 where she managed a portfolio of nanotechnology research projects and centers in the Alliance for Nanotechnology in Cancer program. She also developed new research initiatives such as the Innovative Research in Cancer Nanotechnology program and participated on several NIH and interagency committees and working groups, especially those focused on nanotechnology data sharing. She received her Bachelor's degree in Biology and Neuroscience and Behavior (dual majors) from